A new study has found that stimulant medications and one type of non-stimulant are effective at reducing core symptoms of attention deficit hyperactivity disorder (ADHD) in adults. However, these treatments did not improve overall quality of life.
Researchers reviewed over 100 randomised control trials involving almost 15,000 adult participants to assess the efficacy and acceptability of 16 different treatments for ADHD. The study found that stimulant medications, such as dexamphetamine and methylphenidate, were effective in reducing core symptoms of hyperactivity, impulsivity, and inattention.
Atomoxetine, a non-stimulant medication, was also found to be effective in reducing core symptoms, but it had lower patient acceptance due to side effects. The study suggests that stimulants and atomoxetine are the only treatments that effectively reduce core symptoms of ADHD in adults in the short-term.
However, the study did not find any evidence that these treatments improved overall quality of life or executive functioning. In fact, some non-pharmacological interventions, such as cognitive behavioural therapy and mindfulness, showed promise on clinician-reported ratings but not on self-reported measures.
Experts emphasize that more research is needed to understand the long-term effects of ADHD interventions, including their impact on quality of life. They also highlight the need for a multimodal approach that considers functional and emotional wellbeing in addition to reducing core symptoms.
The study’s findings have implications for clinicians and patients seeking treatment for ADHD. While medications show promise in reducing symptoms, experts stress that individualized treatment plans should be developed based on each person’s unique needs and circumstances.
Source: https://www.abc.net.au/news/health/2024-12-18/adhd-medication-study-symptoms-acceptable-effective-treatment/104734584